Cargando…

Molecular Biomarkers for the Early Detection of Ovarian Cancer

Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and often occurs due to a lack of specific symptoms and effective biomarkers for an early detection. Currently, cancer ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ruiqian, Siu, Michelle K. Y., Ngan, Hextan Y. S., Chan, Karen K. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569881/ https://www.ncbi.nlm.nih.gov/pubmed/36233339 http://dx.doi.org/10.3390/ijms231912041

Ejemplares similares

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
por: Yung, Mingo M. H., et al.
Publicado: (2022)

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis
por: Chan, Karen K. L., et al.
Publicado: (2017)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer
por: Helali, Aya El, et al.
Publicado: (2022)

Patient-Initiated Follow-Up in Ovarian Cancer
por: Luk, Hiu Mei, et al.
Publicado: (2023)

The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
por: Wang, Huogang, et al.
Publicado: (2021)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

Early Detection Biomarkers for Ovarian Cancer
por: Sarojini, Sreeja, et al.
Publicado: (2012)

Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer
por: Liu, Michelle X., et al.
Publicado: (2013)

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
por: Siu, Michelle K. Y., et al.
Publicado: (2012)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
por: Siu, Michelle K. Y., et al.
Publicado: (2015)

Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
por: Mo, Yulan, et al.
Publicado: (2023)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
por: Lok, Gabriel T. M., et al.
Publicado: (2011)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
por: Wei, Na, et al.
Publicado: (2009)

Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer
por: Han, Chae Young, et al.
Publicado: (2021)

Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

Correction to: Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

HPV Vaccination Intentions of Female Students in Chinese Universities: A Systematic Literature Review and Meta-Analysis
por: Bai, Yiming, et al.
Publicado: (2022)

Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review
por: Wan, Peter Kok-Ting, et al.
Publicado: (2020)

Urine Biomarkers for the Early Detection of Ovarian Cancer – Are We There Yet?
por: Grayson, Kelly, et al.
Publicado: (2019)

TAp73-Mediated the Activation of C-Jun N-Terminal Kinase Enhances Cellular Chemosensitivity to Cisplatin in Ovarian Cancer Cells
por: Zhang, Pingde, et al.
Publicado: (2012)

Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis
por: Wang, Xueyu, et al.
Publicado: (2021)

Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance
por: Zhao, Fung, et al.
Publicado: (2014)

Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center
por: Chan, Karen Kar Loen, et al.
Publicado: (2020)

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
por: Yung, Mingo M. H., et al.
Publicado: (2015)

Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
por: Chen, Rain R., et al.
Publicado: (2019)

New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer
por: Hossain, K. R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_odum8ak7h2q39v7it9el4hvapj